PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY- 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Abstract
Authors
J Simsarian A AL-Sabbagh R Bennett B Stubinski G Pardo